ArticleStem cell reviews and reports2026
Characterization and Validation of Long-Term Cultured TERT-Immortalized Human Wharton's Jelly-Derived Mesenchymal Stromal Cells.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) have demonstrated efficacy and feasibility in numerous preclinical and clinical studies. However, their application is limited at early passages owing to replicative senescence. This study investigated whether MSCs immortalized via human telomerase reverse transcriptase (TERT) overexpression (TERT-MSCs) maintain their characteristics and efficacy after extended passaging. Human Wharton’s jelly-derived MSCs at passage (P) 6 were immortalized by retroviral transfection with human TERT. TERT-MSCs at mid (P13) and late (P30) passages were analyzed. Their morphology, differentiation potential, and surface marker expression were preserved throughout extended passaging. Single-cell RNA sequencing reconfirmed the characteristics of TERT-MSCs and compared their gene expression profiles with those of P8 parental (control) cells. As passage number increased, control MSCs exhibited gradual declines in TERT expression, telomere length, and cytoprotective effects, whereas both P13 and P30 TERT-MSCs retained these properties. Expression levels of paracrine-related genes and enriched Gene Ontology terms in extended-passage TERT-MSCs were comparable to those of control MSCs. These findings suggest that TERT-MSCs maintain the key characteristics and therapeutic potential of early-passage MSCs through extended culture, offering a promising approach to overcome the limitations of early-passage MSCs in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.